主管会计工作的公司负责人 公司会计机构负责人: -- 赛降药业集团股份有限公司2023年1-6月非经营性资金占用及其他关联资金往来情况汇总表 | 编制单位:赛隆药业集团股份有限公司 | | | | | | | | | 单位: 万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 占用方与 上市公司 | 上市公司核 2023年期初 | 2023年1-6月占 2023年1-6月 用累计发生金 | | 2023年1-6 | 2023年6月30 | 占用形成原因 | 占用性质 | | | 资金占用方名称 | 的关联关 | 算的会计科 占用资金 E 余额 | 额(不含利 | L L L L L L L L L L A L AR 利息(如有) | 计发生金 | 日占用资金余 额 | | | | | | 系 | | 息) | | 额 | | | | | 控股股东、实际控制 | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | 小计 | | --- | - | | | ...

证券代码：002898 证券简称：赛隆药业 公告编号：2023-045 赛隆药业集团股份有限公司 第三届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 赛隆药业集团股份有限公司（以下简称"公司"）第三届监事会第十一次会 议通知于 2023 年 8 月 13 日以专人送达、电子邮件、电话相结合的方式送达各位 监事。会议于 2023 年 8 月 23 日在湖南省长沙市长沙县星沙产业基地红枫路 1 号湖南赛隆药业（长沙）有限公司会议室以现场和通讯相结合的方式召开，本次 会议应出席监事 3 人，实际出席监事 3 人。会议由监事会主席邓拥军先生召集和 主持。本次会议的召集、召开程序符合《公司法》等有关法律、法规、规范性文 件及《公司章程》的规定。 具体内容详见同日刊登于巨潮资讯网（www.cninfo.com.cn）上的《关于续 聘公司 2023 年度审计机构的公告》（公告编号：2023-047）。 监事会认为：致同会计师事务所（特殊普通合伙）具有证券从业资格，在执 业过程中坚持独立审计原则，能按时为公司出具各项专业报 ...

第三届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 赛隆药业集团股份有限公司（以下简称"公司"）第三届董事会第十五次会 议通知于 2023 年 8 月 13 日以书面方式通过专人送出、传真、电子邮件相结合的 方式送达各位董事。会议于 2023 年 8 月 23 日在珠海市吉大海滨南路 47 号光大 国际贸易中心二楼西侧公司会议室以现场及通讯相结合的方式召开，会议应到董 事 9 人，实际出席董事 9 人，会议由公司董事长蔡南桂先生主持，公司监事和高 级管理人员列席本次会议。本次会议的召集、召开和表决符合有关法律、行政法 规、其他规范性文件和《公司章程》的规定。 证券代码：002898 证券简称：赛隆药业 公告编号：2023-044 赛隆药业集团股份有限公司 具体内容详见同日刊登于巨潮资讯网（www.cninfo.com.cn）上的《公司未 来三年（2023-2025 年）股东回报规划》。 表决结果：表决票数 9 票，赞成 9 票，反对 0 票，弃权 0 票。 二、董事会会议审议情况 1.审议并通过了《关于<2 ...

证券代码：002898 证券简称：赛隆药业 公告编号：2023-043 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）于近日接到公司持股 5%以 上股东珠海横琴新区赛隆聚智投资有限公司（以下简称"赛隆聚智"）的通知， 获悉赛隆聚智将其持有的本公司部分股份办理了解除质押手续，具体事项如下： 股东名 称 是否为控股 股东或第一 大股东及其 解除质 押股数 质押开 始日期 原质押 到期日 期 质押解 除日期 质权人 一、股东本次股份解除质押的基本情况 | | 一致行动人 | | | 期 | | | 股份比例 | | --- | --- | --- | --- | --- | --- | --- | --- | | 赛隆 | 否 | 824,000 | 2022.12 | 2023.12 | 2023.08 | 海通证券股份有 | 5.68% | | 聚智 | | 股 | .08 | .08 | .18 | 限公司 | | | | 二、股份累计被质押的情况 | | | | | | | | | | | | | | | 已质押 ...

证券代码：002898 证券简称：赛隆药业 公告编号：2023-042 赛隆药业集团股份有限公司 关于股价异动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 赛隆药业集团股份有限公司（以下简称"公司"或"本公司"），公司股票（证 券简称：赛隆药业，证券代码：002898）于 2023 年 8 月 14 日、8 月 15 日连续 2 个交易日累计偏离 21.80%，根据深圳证券交易所有关规定，属于股票异常波动 情况。 二、公司关注并核实情况的说明 2.公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 3.近期公司经营情况及内外部经营环境未发生重大变化； 4.经核查，公司、控股股东和实际控制人不存在关于本公司的应披露而未披 露的重大事项，或处于筹划阶段的重大事项； 5.经核查，公司控股股东、实际控制人在股票异动期间不存在买卖公司股票 的行为； 6.经自查，公司不存在违反公平信息披露规定的其他情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易 ...

编号：2023-001 | | 时，公司多个产品在省级及省际联盟集采中中标。感谢 | | --- | --- | | | 关注！ | | | 7、问：请问公司未来是否会继续实施股权激励计划？ | | | 答：投资者您好，股权激励是公司长效激励机制之一， | | | 具体将根据发展需要并综合多方面因素而定，如公司有 | | | 相关进展将在公司指定信披媒体披露，请您及时关注， | | | 谢谢！ | | | 8、问：在研原料药及注射剂有何新的进展可以分享？ | | | 答：投资者您好，请您关注公司 2022 年年度报告第三节 | | | 管理层讨论与分析/四、主营业务分析/1、概述中重点品 | | | 种研发进度，谢谢！ | | | 9、问：现在股东人数是多少？ | | | 答：投资者您好，截至 2023 年 3 月 31 日，公司股东人 | | | 数为 16,662 人，谢谢关注! | | | 10、问：怎样应对带量采购所带来的药品降价压力？ | | | 答：投资者您好，公司将充分发挥"原料药+制剂"的全 | | | 产业链优势，牢牢秉持"以科技领先，成就健康事业" | | | 的企业宗旨，聚焦主业，做大做 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）2022年年度报告及其摘要 已于2023年4月20日刊登于巨潮资讯网（http://www.cninfo.com.cn）。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年5 月9日（星期二）下午15:00至17:00在"赛隆药业投资者关系"小程序举行2022 年度网上业绩说明会。本次网上业绩说明会将采用网络远程的方式举行，投资者 可登陆"赛隆药业投资者关系"小程序参与互动交流。为广泛听取投资者的意见 和建议，提前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信小程序中搜索"赛隆药业投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"赛隆药业投资者关系"小程序，即可参与交流。 出席本次网上说明会的人员有：董事长：蔡南桂先生、董事会秘书：张旭女 士、财务总监：高京先生、独立董事：李公奋先生。 证券代码：002898 证券简称：赛隆药业 公告编号：2023-038 赛隆药业集团股份有限公司 关于举办202 ...

Financial Performance - The company's revenue for Q1 2023 was ¥79,427,813.05, representing a 27.68% increase compared to ¥62,208,999.46 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥3,197,374.56, a significant increase of 149.63% from ¥1,280,860.47 in the previous year[4] - The net profit excluding non-recurring gains and losses was ¥937,954.39, compared to a loss of ¥2,162,519.46 in the same period last year, marking a 143.37% improvement[4] - The basic earnings per share for Q1 2023 was ¥0.0182, up 149.32% from ¥0.0073 in the previous year[4] - Total operating revenue for Q1 2023 was CNY 79,427,813.05, an increase of 27.6% compared to CNY 62,208,999.46 in Q1 2022[15] - Net profit for Q1 2023 reached CNY 3,197,374.56, representing a significant increase of 149.9% from CNY 1,280,860.47 in Q1 2022[16] - Basic and diluted earnings per share for Q1 2023 were CNY 0.0182, compared to CNY 0.0073 in the same period last year, marking an increase of 149.3%[17] Cash Flow and Investments - The company's cash flow from operating activities improved by 70.84%, with a net outflow of ¥5,552,217.03 compared to ¥19,037,470.33 in the same period last year[4] - Cash flow from investing activities increased by 129.30%, driven by higher fixed asset investments during the quarter[7] - The total cash inflow from operating activities was CNY 69,222,319.23, compared to CNY 43,941,902.00 in the same period last year, reflecting a growth of 57.5%[18] - The net cash flow from investment activities was -5,116,248.02, compared to -2,231,243.99 in the previous year, indicating a significant increase in cash outflow for investments[20] - The cash outflow for the acquisition of fixed assets, intangible assets, and other long-term assets was 5,188,807.95, compared to 5,820,680.42 in the previous year[20] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥827,259,456.27, a decrease of 2.44% from ¥847,991,091.15 at the end of the previous year[4] - Current assets decreased to CNY 236,594,634.75 from CNY 254,357,080.25 at the beginning of the year[11] - Cash and cash equivalents decreased to CNY 47,343,347.90 from CNY 72,269,804.86 at the beginning of the year[11] - The company's total liabilities as of Q1 2023 were CNY 297,713,389.58, a decrease from CNY 321,642,399.02 in Q1 2022[16] - Total current liabilities decreased to CNY 242,231,470.19 from CNY 296,451,407.07 at the beginning of the year[12] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,662[8] - The largest shareholder, Cai Nanguai, holds 51.15% of the shares, totaling 90,016,937 shares, with 67,512,703 shares pledged[8] Research and Development - Research and development expenses rose by 75.66%, reflecting increased investment in R&D activities[7] - Research and development expenses for Q1 2023 totaled CNY 7,277,255.13, up from CNY 4,142,780.79 in the previous year, indicating a 75.5% increase[15] Other Financial Metrics - The company reported a fair value change gain of CNY 1,975,851.43 in Q1 2023, down from CNY 4,020,856.24 in Q1 2022[16] - The ending cash and cash equivalents balance was 46,377,644.90, down from 89,272,183.43 in the previous year, indicating a decrease in liquidity[20] - The company did not conduct an audit for the first quarter report, which may affect the perception of financial reliability[21]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15%[15]. - The net profit attributable to shareholders was RMB 300 million, reflecting a growth of 10% compared to the previous year[15]. - The company's operating revenue for 2022 was ¥264,192,655.91, an increase of 6.93% compared to ¥247,078,587.51 in 2021[20]. - The net profit attributable to shareholders for 2022 was -¥37,312,348.43, representing a decrease of 59.85% from -¥23,341,400.64 in 2021[20]. - The cash flow from operating activities for 2022 was ¥14,124,685.73, down 60.17% from ¥35,461,284.13 in 2021[20]. - The company achieved operating revenue of RMB 264.19 million and a net profit attributable to shareholders of RMB -37.31 million in 2022[46]. - The company reported a significant increase in non-operating income, totaling ¥17,156,604.29 in 2022 compared to ¥15,987,325.21 in 2021[25]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2022, representing a year-over-year growth of 20%[169]. User Growth and Market Expansion - User data indicated an increase in active users by 20%, reaching a total of 5 million users by the end of 2022[15]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[15]. - The company plans to continue expanding its market presence and product offerings in the pharmaceutical sector[49]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its product offerings[115]. - The company is actively participating in national and provincial drug procurement initiatives to increase market share and sales volume[87]. Research and Development - The company has allocated RMB 100 million for research and development in 2023, focusing on advanced drug delivery systems[15]. - The company is focusing on innovation-driven transformation in the pharmaceutical industry, aligning with national policies encouraging research and development[31]. - The company is enhancing its digital marketing strategies to improve user engagement and retention rates[114]. - Investment in R&D increased by 25% in 2022, totaling 300 million RMB, focusing on innovative drug development and new technologies[169]. - The company is developing multiple new products, including left pantoprazole sodium and right lansoprazole, which are currently under review for approval[64][65]. Financial Management and Governance - The company has established independent financial accounting departments and maintains independent bank accounts, ensuring no interference from controlling shareholders in financial decisions[105]. - The company has a comprehensive financial management system in place, adhering to relevant accounting standards and regulations[105]. - The company has a robust governance structure, including a board of directors and independent directors, to enhance management and oversight functions[106]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 53.915 million yuan[124]. - The remuneration decision-making process involves the board's remuneration and assessment committee, which submits proposals for approval by the board and shareholders[123]. Environmental and Safety Compliance - The company complies with all relevant environmental protection laws and regulations, maintaining necessary permits for its subsidiaries[152]. - The environmental management system is aligned with national and local environmental protection standards, ensuring responsible operational practices[151]. - The company has established a dedicated safety and environmental protection department to manage wastewater and air pollution treatment facilities[156]. - The company emphasizes environmental protection by prioritizing eco-friendly technologies and equipment in its production processes[160]. - The company has developed a comprehensive emergency response plan for environmental pollution incidents, ensuring preparedness and effective response[158]. Challenges and Risks - The company faces risks related to industry policy changes and new drug development, which could impact future performance[4]. - The company is facing risks related to changes in industry policies, which could impact its operations and strategic direction[91]. - New drug development involves high investment and risk, with potential project failures if safety and efficacy standards are not met[92]. - The company must navigate risks related to the expiration of necessary certifications and licenses, which could impact future operations[94]. Strategic Outlook - The management provided guidance for 2023, projecting a revenue growth of 18% and a net profit increase of 12%[15]. - The company provided a positive outlook for 2023, projecting a revenue growth of 15% to 1.725 billion RMB, driven by new product launches and market expansion efforts[169]. - The company aims to reduce operational costs by 10% in 2023 through efficiency improvements and process optimization[169]. - The company is committed to sustainability initiatives, aiming to reduce its carbon footprint by 20% over the next five years[116].

Financial Performance - The company's revenue for Q3 2022 was ¥61,471,357.81, representing a 9.00% increase year-over-year[5] - Net profit attributable to shareholders decreased by 72.94% to ¥645,385.75, while the net profit after deducting non-recurring gains and losses was -¥2,437,223.98, a decrease of 1,269.27%[5] - Total operating revenue for Q3 2022 was CNY 192,836,032.37, an increase of 4.8% compared to CNY 185,425,358.96 in the same period last year[20] - Net profit for Q3 2022 was CNY 1,697,041.91, a decrease of 85.6% from CNY 11,800,954.52 in Q3 2021[21] - Basic and diluted earnings per share for Q3 2022 were CNY 0.0096, down from CNY 0.0671 in the same quarter last year[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥865,697,964.81, down 1.94% from the end of the previous year[5] - Total current assets as of September 30, 2022, amount to CNY 269,064,623.01, a decrease from CNY 289,141,208.78 at the beginning of the year[17] - Total liabilities as of the end of Q3 2022 were CNY 300,339,882.34, a decrease from CNY 319,123,549.87 at the end of Q3 2021[21] - Non-current assets total CNY 596,633,341.80, slightly up from CNY 593,643,381.65[17] Cash Flow - The company’s cash flow from operating activities showed a net outflow of -¥6,959,283.72, a significant decrease of 276.88%[5] - Cash inflow from operating activities was CNY 182,336,417.97, compared to CNY 173,105,200.23 in Q3 2021[23] - Net cash flow from operating activities was -6,959,283.72, compared to 3,934,504.24 in the previous year, indicating a decline in operational performance[24] - Total cash outflow from operating activities amounted to 189,295,701.69, up from 169,170,695.99 year-over-year[24] Expenses - The gross profit margin decreased due to an increase in operating costs, which rose by 30.74% to ¥76,768,235.34[9] - Total operating costs for Q3 2022 were CNY 194,631,932.78, up 8.2% from CNY 179,954,786.92 in Q3 2021[20] - Research and development expenses for Q3 2022 amounted to CNY 17,743,407.29, an increase of 18.5% from CNY 14,988,989.35 in Q3 2021[21] - The company paid 34,865,231.00 in employee compensation, an increase from 30,710,939.77 in the previous year[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,357[13] - The largest shareholder, Cai Nanguai, holds 51.15% of shares, totaling 90,016,937 shares, with 67,512,703 shares pledged[13] - Total equity attributable to shareholders of the parent company was CNY 565,358,082.47, slightly up from CNY 563,661,040.56 in the previous year[21] Other Financial Metrics - The company received tax refunds amounting to ¥18,195,010.28, a substantial increase of 6,804.16% compared to the previous period[11] - Tax payments amounted to 12,102,323.46, slightly lower than 13,945,585.57 in the same period last year[24] - The company recorded a fair value gain of CNY 9,528,359.89 in Q3 2022, compared to CNY 3,750,252.83 in Q3 2021[21] - The company reported a significant increase in accounts receivable by 43.62% to ¥84,412,286.24, attributed to increased credit sales[8]